While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Narasimhan’s appointment underscores the growing importance of AI in transforming drug discovery
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Subscribe To Our Newsletter & Stay Updated
